UBS Group’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$99.8M Sell
408,100
-185,996
-31% -$43.3M 0.02% 1050
2025
Q4
$123M Sell
594,096
-26,099
-4% -$5.16M 0.02% 871
2025
Q3
$115M Buy
620,195
+92,463
+18% +$15.8M 0.02% 928
2025
Q2
$80.6M Sell
527,732
-180,963
-26% -$27.8M 0.01% 1125
2025
Q1
$118M Sell
708,695
-424,800
-37% -$66.5M 0.02% 824
2024
Q4
$164M Buy
1,133,495
+224,000
+25% +$34.7M 0.03% 614
2024
Q3
$147M Buy
909,495
+306,000
+51% +$48.8M 0.03% 536
2024
Q2
$88.2M Buy
603,495
+98,100
+19% +$14.6M 0.02% 709
2024
Q1
$79.9M Sell
505,395
-191,942
-28% -$30.6M 0.02% 760
2023
Q4
$109M Buy
697,337
+397,537
+133% +$61M 0.03% 534
2023
Q3
$46.7M Buy
299,800
+45,870
+18% +$7.57M 0.02% 902
2023
Q2
$42M Buy
253,930
+106,600
+72% +$17.2M 0.01% 928
2023
Q1
$22.8M Sell
147,330
-84,070
-36% -$13.6M 0.01% 1299
2022
Q4
$40.9M Buy
231,400
+70,570
+44% +$12.2M 0.02% 922
2022
Q3
$26.3M Buy
160,830
+69,630
+76% +$11.8M 0.01% 1091
2022
Q2
$16.2M Sell
91,200
-44,500
-33% -$7.93M 0.01% 1462
2022
Q1
$24.1M Sell
135,700
-116,500
-46% -$19.8M 0.01% 1292
2021
Q4
$43.1M Buy
252,200
+135,979
+117% +$22.3M 0.01% 1053
2021
Q3
$18.8M Sell
116,221
-50,200
-30% -$8.56M 0.01% 1547
2021
Q2
$27.4M Sell
166,421
-385,200
-70% -$63.8M 0.01% 1246
2021
Q1
$90.7M Buy
551,621
+457,721
+487% +$74.1M 0.03% 556
2020
Q4
$14.8M Buy
93,900
+1,700
+2% +$251K 0.01% 1555
2020
Q3
$13.7M Buy
92,200
+77,200
+515% +$11.4M 0.01% 1429
2020
Q2
$2.11M Sell
15,000
-527,200
-97% -$76.8M ﹤0.01% 2822
2020
Q1
$71.1M Buy
542,200
+477,000
+732% +$67.7M 0.03% 438
2019
Q4
$9.51M Buy
65,200
+54,300
+498% +$7.37M ﹤0.01% 2002
2019
Q3
$1.41M Sell
10,900
-300
-3% -$39.5K ﹤0.01% 3652
2019
Q2
$1.56M Sell
11,200
-101,600
-90% -$14.1M ﹤0.01% 3374
2019
Q1
$15.8M Buy
112,800
+100,370
+807% +$13.4M 0.01% 1318
2018
Q4
$1.6M Buy
12,430
+8,800
+242% +$1.23M ﹤0.01% 3252
2018
Q3
$502K Sell
3,630
-319,386
-99% -$42.4M ﹤0.01% 4399
2018
Q2
$39.2M Sell
323,016
-77,184
-19% -$9.63M 0.02% 780
2018
Q1
$51.3M Buy
400,200
+316,400
+378% +$42.8M 0.02% 628
2017
Q4
$11.7M Buy
83,800
+34,750
+71% +$4.84M ﹤0.01% 1594
2017
Q3
$6.38M Sell
49,050
-260,950
-84% -$34.6M ﹤0.01% 1990
2017
Q2
$41M Buy
310,000
+400
+0.1% +$51K 0.02% 658
2017
Q1
$38.6M Buy
309,600
+77,300
+33% +$9.23M 0.02% 661
2016
Q4
$26.8M Buy
232,300
+65,800
+40% +$7.6M 0.01% 851
2016
Q3
$19.7M Buy
166,500
+90,685
+120% +$11M 0.01% 993
2016
Q2
$9.2M Sell
75,815
-51,985
-41% -$5.91M 0.01% 1444
2016
Q1
$13.8M Sell
127,800
-115,900
-48% -$12M 0.01% 1112
2015
Q4
$25M Buy
243,700
+127,300
+109% +$12.8M 0.02% 834
2015
Q3
$10.9M Sell
116,400
-128,954
-53% -$12.5M 0.01% 1309
2015
Q2
$23.9M Buy
245,354
+149,654
+156% +$15M 0.02% 864
2015
Q1
$9.63M Buy
95,700
+55,600
+139% +$5.65M 0.01% 1512
2014
Q4
$4.19M Buy
+40,100
New +$4.23M ﹤0.01% 2246

Other funds holding JNJ

UBS Group's JNJ Position: Q1 2026 in Review

UBS Group increased its Johnson & Johnson (JNJ) stake by 2.3% in Q1 2026, buying an estimated $52.4M and bringing the position to 10,209,327 shares worth $2.5B. The position accounts for 0.37% of the portfolio, ranked #33.

UBS Group first reported a position in JNJ in Q4 2014 and has held it in 46 quarters since. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • UBS Group held 10,209,327 shares of Johnson & Johnson worth $2.5B as of Q1 2026.
  • UBS Group bought 225,036 Johnson & Johnson shares in Q1 2026, an estimated $52.4M.
  • Johnson & Johnson made up 0.37% of UBS Group's portfolio in Q1 2026, its #33 holding.
  • UBS Group first reported a position in Johnson & Johnson in Q4 2014 and has held it in 46 quarters since.
  • 4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.